PHI with Concentric periaxialis encephalomyelitis
How does this condition affect your private health insurance?
Encephalomyelitis periaxialis concentrica, or Baló's concentric sclerosis, is a rare and severe inflammatory demyelinating disease, often considered a variant of multiple sclerosis. It is characterized by distinctive concentric rings of demyelination in the brain's white matter, visible on MRI. Clinically, it manifests with rapidly progressive neurological deficits, including motor weakness, sensory loss, cognitive dysfunction, and vision impairment. The underlying cause is believed to be an autoimmune process targeting myelin. Its unique pathological pattern distinguishes it. Diagnosis relies heavily on characteristic imaging findings. Treatment involves high-dose corticosteroids and other immunomodulatory therapies, aiming to reduce inflammation and slow progression. The prognosis is highly variable, often severe, with a significant risk of disability and mortality.
PKV Risk Assessment
Individual, specialized PHI providers may still insure you, but with a significant surcharge.
Impact on Your Insurance Policy
Duration of Illness (Initial)
Rapid onset, often progressing over days to weeks.
Duration of Illness (Lifetime)
Can be monophasic with severe acute course, or rarely recurrent. Often leads to chronic disability or early mortality.
Cost of Treatment (Initial)
High (e.g., tens of thousands to hundreds of thousands of USD), involving hospitalization, intensive care, specialized diagnostics, and high-dose immunotherapies.
Cost of Treatment (Lifetime)
Very high (e.g., hundreds of thousands to millions of USD) due to potential for chronic care, rehabilitation, ongoing medication, and managing severe disability.
Mortality Rate
Moderate to High, especially in severe acute forms without prompt treatment, ranging from 10% to 50% or more depending on severity and access to care.
Risk of Secondary Damages
Very High (over 80-90%), including severe neurological deficits, cognitive impairment, motor disability, and sensory loss.
Probability of Full Recovery
Low (less than 10-20%), especially without any residual neurological deficits. Partial recovery is possible but often with lasting impairments.
Underlying Disease Risk
Low directly, but it is considered a rare variant within the spectrum of demyelinating diseases like Multiple Sclerosis. No strong association with other specific diseases.